Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2010 3
2011 4
2012 10
2013 13
2014 12
2015 18
2016 13
2017 14
2018 15
2019 15
2020 18
2021 23
2022 18
2023 29
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hung hung hsu (32 results)?
Reply.
Huang SC, Su TH, Kao JH. Huang SC, et al. Among authors: su th. Clin Gastroenterol Hepatol. 2024 Feb 5:S1542-3565(24)00106-X. doi: 10.1016/j.cgh.2024.01.028. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38320680 No abstract available.
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Hirode G, et al. Among authors: su th. Gastroenterology. 2022 Mar;162(3):757-771.e4. doi: 10.1053/j.gastro.2021.11.002. Epub 2021 Nov 9. Gastroenterology. 2022. PMID: 34762906
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q, Klein C, Caruso S, Maille P, Allende DS, Mínguez B, Iavarone M, Ningarhari M, Casadei-Gardini A, Pedica F, Rimini M, Perbellini R, Boulagnon-Rombi C, Heurgué A, Maggioni M, Rela M, Vij M, Baulande S, Legoix P, Lameiras S; HCC-AI study group; Bruges L, Gnemmi V, Nault JC, Campani C, Rhee H, Park YN, Iñarrairaegui M, Garcia-Porrero G, Argemi J, Sangro B, D'Alessio A, Scheiner B, Pinato DJ, Pinter M, Paradis V, Beaufrère A, Peter S, Rimassa L, Di Tommaso L, Vogel A, Michalak S, Boursier J, Loménie N, Ziol M, Calderaro J. Zeng Q, et al. Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8. Lancet Oncol. 2023. PMID: 37951222
Reply.
Su TH, Chen CL, Kao JH. Su TH, et al. Hepatology. 2016 Nov;64(5):1814. doi: 10.1002/hep.28578. Epub 2016 Jun 1. Hepatology. 2016. PMID: 27019093 No abstract available.
Halfway through HBV elimination - are we not waiting?
Wong GL, Ong JP, Kaewdech A, Su TH. Wong GL, et al. Among authors: su th. Int J Infect Dis. 2023 Sep;134:299-300. doi: 10.1016/j.ijid.2023.07.028. Epub 2023 Jul 26. Int J Infect Dis. 2023. PMID: 37507084 Free article. No abstract available.
177 results